Mandate

Vinge advised Wilson Therapeutics in connection with its IPO

May 13, 2016

Vinge has advised Wilson Therapeutics AB (publ) in connection with its IPO on Nasdaq Stockholm. The price in the offering was set at SEK 49 per share, corresponding to a
market capitalization of approximately SEK 1,305 million for the total number of outstanding shares in the company (provided that the over-allotment option is utilized).

Vinge’s team primarily consisted of Jesper Ottergren, Erik Sjöman, Christian Lindhé, Ludvig Frithiof, Kristoffer Franzkeit and Astrid Karlsson.

Related

Vinge has advised EQT AB in connection with the refinancing of EQT’s EUR 1,500,000,000 sustainability-linked revolving credit facility

The sustainability-linked credit facility has a tenor of 5 years with two 1-year extension options.
July 23, 2024

Vinge has advised Embracer Group in connection with a EUR 600 million multicurrency revolving facility agreement

Vinge has advised Embracer Group in connection with a EUR 600 million multicurrency revolving facility agreement entered into with BNP Paribas, Citibank Europe, DNB, JP Morgan, Nordea, SEB and Swedbank.
July 19, 2024

Vinge has advised SBB and Sveafastigheter in connection with an exchange offer

Vinge has advised Samhällsbyggnadsbolaget i Norden AB (SBB) and Sveafastigheter AB in connection with an exchange offer directed to investors in SBB’s outstanding bonds, whereby investors exchanged senior and hybrid bonds in SBB for new senior bonds issued in Sveafastigheter AB. The existing bonds were partly issued under SBB’s EMTN programme, partly on a standalone basis. Following the transaction, the investors have been slotted in under Swedish bond terms on a standalone basis.
July 09, 2024